文献速递核素与放射性配体治疗肿瘤 PET/CT

Bellmunt风险评分可预测接受PSMA靶向放射配体治疗的转移性去势抵抗性前列腺癌男性患者的生存

Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN).
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-08-02

本研究回顾性纳入386例在本中心接受[177Lu]Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,评估Bellmunt风险评分(BRS)对总生存(OS)的预测价值。BRS是多变量分析中OS的独立预测因子,评分0、1、2、3分患者的中位OS分别为17.6、10.9、6.6和2.7个月(Log-Rank P < 0.001)。加入C反应蛋白(CRP)的增强版评分可进一步提高预后准确性。

要点

  • BRS是多变量分析中mCRPC患者接受[177Lu]Lu-PSMA-617治疗后OS的独立预测因子。
  • BRS评分0、1、2、3分患者的中位OS分别为17.6、10.9、6.6和2.7个月(Log-Rank P < 0.001)。
  • BRS预测1年和2年OS的tAUC分别为71.6%和74.4%,CRP增强版评分分别达75.7%和78.1%。

核心结论

  • Bellmunt风险评分能有效对接受[177Lu]Lu-PSMA-617治疗的mCRPC患者进行风险分层。
  • 该评分设计简单,基于易获取的临床参数,在真实临床环境中具有实用性和应用价值。

研究设计与样本

  • 回顾性评估386例在本中心接受[177Lu]Lu-PSMA-617治疗的mCRPC患者数据。
  • BRS的构建:ECOG体能状态(ECOG PS)> 0、血红蛋白 < 10 g/dL、存在肝转移,每项危险因素计1分。
  • 另开发了纳入C反应蛋白(CRP)> 30 mg/dL的增强版评分和使用半定量ECOG PS的改良版评分。
  • 统计分析包括Cox回归、Kaplan-Meier估计、一致性指数和时间依赖AUC(tAUC)。

主要发现

  • BRS是多变量分析中OS的独立预测因子。
  • BRS评分0、1、2、3分患者的中位OS分别为17.6、10.9、6.6和2.7个月(Log-Rank P < 0.001)。
  • BRS预测1年和2年OS的tAUC分别为71.6%和74.4%。
  • CRP增强版评分进一步提高预后准确性,预测1年OS的tAUC为75.7%,2年OS的tAUC为78.1%。

关键数值与推荐

  • BRS危险因素:ECOG PS > 0、血红蛋白 < 10 g/dL、存在肝转移,每项计1分。
  • CRP增强版评分额外纳入CRP > 30 mg/dL。
  • BRS评分0、1、2、3分对应的中位OS分别为17.6、10.9、6.6和2.7个月(Log-Rank P < 0.001)。
  • BRS预测1年和2年OS的tAUC分别为71.6%和74.4%;CRP增强版评分分别为75.7%和78.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: [177Lu]Lu-PSMA-617 therapy has emerged as a promising radioligand treatment for metastatic castration-resistant prostate cancer (mCRPC). Given the overall poor prognosis of mCRPC, accurately predicting the key endpoint overall survival (OS) remains an ongoing challenge, crucial for optimizing risk/benefit assessment prior to treatment. This study investigates the prognostic utility of the simple designed Bellmunt Risk Score (BRS) in mCRPC patients treated with [177Lu]Lu-PSMA-617. METHODS: We retrospectively evaluated data from 386 mCRPC patients who had received [177Lu]Lu-PSMA-617 therapy at our center. BRS was constructed by attributing one point for each of the following risk factors: ECOG performance status (ECOG PS) > 0, hemoglobin < 10 g/dL, and the presence of liver metastases. Additionally, an enhanced version of the score including C-reactive protein (CRP) > 30 mg/dL and a modified version utilizing a semi-quantitative ECOG PS were developed. Statistical analysis included Cox regression, Kaplan-Meier estimates, concordance indices and time-dependent area under the curve (tAUC). RESULTS: The BRS served as an independent predictor of OS in multivariable analysis. The estimated median OS was 17.6, 10.9, 6.6, and 2.7 months for patients with scores of 0, 1, 2 and 3, respectively (Log-Rank P < 0.001). The tAUC values for predicting 1-year and 2-year OS were 71.6% and 74.4%, respectively. The CRP-enhanced score further improved prognostic accuracy, achieving tAUCs of 75.7% for 1-year OS and 78.1% for 2-year OS. CONCLUSION: The Bellmunt Risk Score effectively stratifies mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy. Its straightforward design, based on readily accessible clinical parameters, ensures practicality and utility in real-world clinical settings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Büttner T, Marinova M, Gaertner FC, et al. Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN). Eur J Nucl Med Mol Imaging. 2025. PMID: 40751808. doi:10.1007/s00259-025-07492-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。